As COVID-19 deaths peaked this spring, Teri Woodhull faced a tough decision on treatments for cancer — a condition that already makes her more vulnerable to the pandemic.
Woodhull could lower her risk of being exposed to the coronavirus by undergoing chemotherapy every three weeks, rather than weekly. But less-frequent treatments are delivered with a stronger dose, raising the possibility of more severe side effects.
"When you're going through treatment for cancer, it's emotional already," said Woodhull, 57, of Minnetonka, who was diagnosed with advanced ovarian cancer in 2010. "When you layer on the stress of not knowing whether the choices you're making might be endangering you even more — it just piles on."
For cancer patients in Minnesota, COVID-19 has altered treatments, paused clinical trials and limited connections with friends and family in the midst of a dreaded diagnosis. Thousands of mammograms and colonoscopies were delayed in March and April as hospitals and clinics marshaled resources to fight COVID-19.
Now, as the health care system slowly returns to pre-COVID norms, doctors are uneasy because patients seem to be steering clear of care, despite reassurances about the safety of health care facilities. One possible consequence is that cancers will be caught later, when treatment options are more difficult.
"A delay of six weeks is probably not going to have a significant oncologic outcome impact or change for any individual patient or even a population," said Dr. Natasha Rueth, a cancer surgeon at Allina Health System. "I'm more worried about the downstream effects of people not coming into the health care system now, and what that's going to mean for future cancer patients."
To conserve supplies for treating COVID-19 patients, Minnesota joined other states in halting elective and nonemergency medical procedures, beginning the evening of March 23. The ban was lifted about seven weeks later, on May 11.
States also issued stay-at-home orders this spring, which further contributed to cancer patients staying away from health care, said Dr. Norman Sharpless, director of the National Cancer Institute, in an editorial in the journal Science. He projected that COVID-19 could result in almost 10,000 excess deaths — an increase of about 1% — beyond the expected toll from breast and colorectal cancer over the next decade.